Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.
Joined May 2009
- Tweets22.6K
- Following512
- Followers40.3K
- Likes540
Struggling to choose between DNA vs. RNA-based NGS for NTRK fusions?
Dr. Ibiayi Dagogo-Jack and Dr. Nabil F. Saba explain why RNA-based assays, and plasma testing when tissue is limited, are critical for detection.
Watch the full discussion ➡️ mdsc.pe/4jb6VFn
#CME #Oncology #NTRK
205
🧬 Choosing the right TKI in CML starts with the right data. Explore first-line selection, navigate resistance & translate mutational analysis into therapeutic decisions with coordinated team-based care. 🎯 Sharpen your CML strategy—register today! mdsc.pe/4zRXX6p #ASH26
191
🧪 Advancing care for systemic mastocytosis starts with the latest evidence happening at #ASH26!
Explore clinical trial findings, assess disease control, and enhance interprofessional treatment decisions.
🚀 Stay informed—join this educational activity! mdsc.pe/4yfvJ3h
191
Proud to sponsor Caregiver Central at @BloodCancerUtd New Jersey's Light The Night in Mercer County. 🏮 Better care starts when clinician education reflects patient and caregiver realities.
pmlive.com/pmhub/medscape_ed…
#LightTheNight #BloodCancerUnited
304
🧠 What does treatment success really look like in hemophilia? Move beyond bleeding rates, compare meaningful differences across therapies, and personalize care around the factors that matter to each patient. 🪄 Bring a fresh perspective to hemophilia care! mdsc.pe/4irU5mb
#ASH26
182
Advance your practice with new education on oral SERD eligibility in EBC. Gain expert insight into landmark trials, learn exactly who qualifies for novel therapies, and elevate the care you deliver and the outcomes you can achieve for the patients you treat every day.
.mdsc.pe/4z5AwF8
233
📌 #ASH26 is BACK! 🚀 Ready to bring bispecific antibodies into R/R MM care? Review key🔑 trial data, navigate barriers to implementation, and explore strategies to manage AEs while expanding access. 🧩 Build individualized care plans with confidence. Save your spot! mdsc.pe/3Sy3Apg
246
🔮 Is your patient’s SM truly under control? Dive into emerging evidence across the spectrum of systemic mastocytosis and 🧬 sharpen your ability to recognize when advanced treatment may be needed. 📣 Bring the latest evidence into practice! mdsc.pe/4yhO28u #ASH26
211
Episodic therapy, not suppression, is often the real risk factor for refractory HSV.
Hear Dr. Anna Wald and Dr. Princy Kumar review why clinical resistance happens and how care is evolving.
Catch the replay ➡️ mdsc.pe/4A89e1B
#InfectiousDisease #CME #MedEd
275
Discover our new curriculum featuring Dr Aditya Bardia, who shares expert perspectives on emerging oral SERD strategies and their potential role in advancing care for patients with early breast cancer.
mdsc.pe/4z5AwF8
ALT This image is a cover for a Medscape Oncology presentation, titled "Preparing for the Next Era in Early Breast Cancer: Integrating Oral SERDs Into Clinical Practice." It features an hourglass with pink sand, set against a background with subtle wave patterns and pink flowers. Roche Group's support is acknowledged at the bottom.
1
278
⏳ The countdown to #ASH26 begins! Save this post now and start planning your must-attend sessions! 📌 From diagnosis to personalized treatment, every decision matters in AL amyloidosis. 🔎 Gain practical insights for interpreting clinical findings 👇 mdsc.pe/4x5jqGX
222
🩸 When rare hematologic conditions challenge the usual playbook, be ready. Decode atypical presentations, 🧬 explore novel targeted therapies & sharpen diagnostic and treatment strategies 🎯 Build confidence for complex cases—secure your spot today! mdsc.pe/46oDsAC
#ASH26
220
🩸 From molecular profiling to treatment selection, MDS care continues to evolve!
Explore emerging clinical evidence and strategies for managing treatment complexities across the disease continuum.
🎯 Advance your expertise! mdsc.pe/47pCQv9
200
🔬 How can you optimize care for patients with newly diagnosed multiple myeloma ?
Explore clinical evidence for transplant-eligible and ineligible patients, personalized treatment strategies, and the importance of collaborative care.
💡 Strengthen your clinical decision-making—join this educational activity! mdsc.pe/3U0ktts #ASH26
221
🔍 MDS treatment decisions are becoming increasingly precise. Discover how cytogenetic and molecular characteristics can guide care, examine trial data 🧪 across the disease continuum & strengthen team-based management of treatment complexities. ⚡ Turn evolving evidence into action—join us! mdsc.pe/4r4FVcQ #ASH26
2
320
🧬 Choosing the right TKI in CML starts with the right data. Explore first-line selection, navigate resistance & translate mutational analysis into therapeutic decisions with coordinated team-based care. 🎯 Sharpen your CML strategy—register today! mdsc.pe/4zRXX6p #ASH26
2
265
💡 How can clinicians translate advances in immuno-oncology into better treatment decisions? Explore antigen-directed therapies, biomarker-driven selection & practical strategies for individualized cancer care. 🔬
📢 Stay ahead of emerging evidence—explore this educational activity today!
🔗 mdsc.pe/4sImjMH
266
🦟 Stay current on dengue prevention! Explore the latest data, strengthen vaccine 💉recommendations, and gain confidence addressing patient questions and concerns about dengue vaccination. 🌎 Click here now: mdsc.pe/4ARfGLF
243
Spotlight on NTRK Fusions: Clinical Care Insights Across Lung and Thyroid Cancer nitter.cf/i/broadcasts/2lgyKAqvq…
1
195
Starting in 1 HOUR ➡️ mdsc.pe/4k9208O
Gain expert insights on NTRK fusions in lung and thyroid cancer. Join LIVE!
🗓️ Today
⏰ 12:00pm EST
#Oncology #NTRKFusions #MedEd
150